Nov 12, 2025
SGLT2 Inhibitors and Bone Health: What You Need to Know About Fracture Risk
Biosimilars offer major cost savings over brand-name biologics, but insurance barriers like prior authorization and same-tier placement make them hard to access. Patients pay nearly the same out-of-pocket costs - defeating the purpose.